PTGX Protagonist Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why PTGX matters now
Protagonist Therapeutics, Inc. (PTGX) is a US stock in Healthcare. The latest InvestLog snapshot shows $154.72 with +0.26% on the session and $9.95B in market capitalization; recent performance reads 1-month +14.73% and YTD +29.22%.
The latest financial table shown here is Q1 2026, with revenue of $56.4M, net income of $3.8M, and EPS of $0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.6%.
The latest indexable market news headline is "Protagonist Therapeutics Reports Granting of Inducement Awards" from Accesswire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $119.00; recent insider activity includes Waddill William D. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
11.21
P/S
98.00
EV/EBITDA
-62.09
DCF Value
$-9.63
FCF Yield
-1.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.5%
Operating Margin
-192.4%
Net Margin
-154.9%
ROE
-17.8%
ROA
-16.4%
ROIC
-21.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $56.4M | $3.8M | $0.05 |
| Q4 2025 | $7.4M | $-44.4M | $-0.69 |
| FY 2025 | $46.0M | $-130.1M | $-2.05 |
| Q3 2025 | $4.7M | $-39.3M | $-0.62 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$117.25
Target (Median)
$119.00
Target Range
$110.00 - $121.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.83
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.